Drug Profile
ADX 415
Alternative Names: ADX-415Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Procter & Gamble
- Developer Shionogi Pharma
- Class Antihypertensives
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hot flashes; Hypertension
Most Recent Events
- 11 Aug 2011 Discontinued - Phase-I/II for Hot flashes in USA (PO)
- 11 Aug 2011 Discontinued - Phase-II for Hypertension in USA (PO)
- 12 Jan 2010 Sciele Pharma is now called Shionogi Pharma